Immunohematologic characteristics and transfusion parameters
| . | BMHSCT donors N = 21 . | PBHSCT donors4-150 N = 20 . | P . |
|---|---|---|---|
| Anti-A Ab titers, median (range) | 2 (0-512) | 8 (0-256) | .38 |
| Anti-B Ab titers, median (range) | 8 (0-64) | 24 (0-512) | .24 |
| BMHSCT recipients N = 28 | PBHSCT recipients N = 21 | ||
| PC transfusions | |||
| Episodes, median (range) | 6 (3-33) | 3 (1-18) | .03 |
| At least one PC transfusion ABO Ag incompatible with the HSC donor | |||
| Yes (N = 26) | 10 (36%) | 9 (43%) | |
| No (N = 23) | 18 (64%) | 12 (57%) | .61 |
| At least one PC transfusion ABO Ag incompatible with both the HSC donor and the recipient | |||
| Yes (N = 10) | 6 (21%) | 4 (19%) | |
| No (N = 39) | 22 (79%) | 17 (81%) | 1 |
| Plasma containing anti-A Ab | |||
| Yes (N = 35) | 19 (68%) | 16 (76%) | |
| No (N = 14) | 9 (32%) | 5 (24%) | .52 |
| Delay,4-151 d, median (range) | 13 (1-40) | 17 (2-33) | .56 |
| Plasma containing anti-B Ab | |||
| Yes (N = 47) | 27 (96%) | 20 (95%) | |
| No (N = 2) | 1 (4%) | 1 (5%) | 1 |
| Delay,4-151 d, median (range) | 11 (2-40) | 17 (2-23) | .17 |
| RBC-C transfusions | |||
| Episodes, median (range) | 3 (0-12) | 3 (0-8) | .34 |
| Patients receiving IVIG | |||
| Yes (N = 23) | 17 (61%) | 9 (43%) | |
| No (N = 26) | 11 (39%) | 12 (57%) | .22 |
| Delay,4-151 d, median (range) | 6 (1-11) | 5 (1-9) | .33 |
| . | BMHSCT donors N = 21 . | PBHSCT donors4-150 N = 20 . | P . |
|---|---|---|---|
| Anti-A Ab titers, median (range) | 2 (0-512) | 8 (0-256) | .38 |
| Anti-B Ab titers, median (range) | 8 (0-64) | 24 (0-512) | .24 |
| BMHSCT recipients N = 28 | PBHSCT recipients N = 21 | ||
| PC transfusions | |||
| Episodes, median (range) | 6 (3-33) | 3 (1-18) | .03 |
| At least one PC transfusion ABO Ag incompatible with the HSC donor | |||
| Yes (N = 26) | 10 (36%) | 9 (43%) | |
| No (N = 23) | 18 (64%) | 12 (57%) | .61 |
| At least one PC transfusion ABO Ag incompatible with both the HSC donor and the recipient | |||
| Yes (N = 10) | 6 (21%) | 4 (19%) | |
| No (N = 39) | 22 (79%) | 17 (81%) | 1 |
| Plasma containing anti-A Ab | |||
| Yes (N = 35) | 19 (68%) | 16 (76%) | |
| No (N = 14) | 9 (32%) | 5 (24%) | .52 |
| Delay,4-151 d, median (range) | 13 (1-40) | 17 (2-33) | .56 |
| Plasma containing anti-B Ab | |||
| Yes (N = 47) | 27 (96%) | 20 (95%) | |
| No (N = 2) | 1 (4%) | 1 (5%) | 1 |
| Delay,4-151 d, median (range) | 11 (2-40) | 17 (2-23) | .17 |
| RBC-C transfusions | |||
| Episodes, median (range) | 3 (0-12) | 3 (0-8) | .34 |
| Patients receiving IVIG | |||
| Yes (N = 23) | 17 (61%) | 9 (43%) | |
| No (N = 26) | 11 (39%) | 12 (57%) | .22 |
| Delay,4-151 d, median (range) | 6 (1-11) | 5 (1-9) | .33 |
PC indicates platelet concentrate; HSC, hematopoietic stem cell; RBC-C, red blood cell concentrate; IVIG, intravenous polyvalent immunoglobulin (Sandoglobulin; laboratoires Sandoz, Reuil Malmaison, France) median dose, 250 mg/kg (range, 50-500); for other abbreviations, see Tables 1, 2, and 3.
Before administration of granulocyte colony-stimulating factor.
Delay between the last transfusion of passive Ab with PC or IVIG administration and day + 30 samples.